Tau and p-tau, proteins traditionally associated with neurodegenerative diseases, are also elevated in patients with OSA compared to those without.12 In contrast to vWF, tau concentrations decrease after 1 year of CPAP treatment, and even stabilize tau and other clinical assessments in patients with OSA and subjective cognitive impairment.13 This evidence concerns the gene MAPT and neurodegenerative disease.